Fresenius Medical Care AG (FMS) Cash & Equivalents (2009 - 2026)

Fresenius Medical Care AG's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 27.86% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 27.86% YoY), while the FY2025 annual figure was $1.9 billion, up 46.96% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.5 billion, down from $1.9 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $320.3 billion in Q3 2025, with the low at $1.1 billion in Q2 2022.
• The 5-year median for Cash & Equivalents is $1.3 billion (2022), against an average of $20.2 billion.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 39.04% in 2022, then surged 20925.85% in 2025.
• Fresenius Medical Care AG's Cash & Equivalents stood at $1.3 billion in 2022, then advanced by 18.16% to $1.5 billion in 2023, then fell by 17.52% to $1.3 billion in 2024, then soared by 46.96% to $1.9 billion in 2025, then fell by 22.06% to $1.5 billion in 2026.
• Business Quant data shows FMS's Cash & Equivalents at $1.5 billion in Q1 2026, $1.9 billion in Q4 2025, and $320.3 billion in Q3 2025.